Envonalkib

Envonalkib
Clinical data
Trade names	安洛晴
Legal status
Legal status	Rx in China;
Identifiers
	IUPAC name 3-[(1R)-1-(2,6-Dichloro-3-fluorophenyl)ethoxy]-5-[4-methoxy-6-[(2S)-2-methylpiperazin-1-yl]-3-pyridinyl]pyridin-2-amine;
CAS Number	1621519-26-3 ;
PubChem CID	76899983 ;
UNII	QB7KTQ7VW9 ;
ChEMBL	ChEMBL5095063 ;
Chemical and physical data
Formula	C24H26Cl2FN5O2
Molar mass	506.40 g·mol−1
3D model (JSmol)	Interactive image ;
	SMILES C[C@H]1CNCCN1C2=NC=C(C(=C2)OC)C3=CC(=C(N=C3)N)O[C@H](C)C4=C(C=CC(=C4Cl)F)Cl;
	InChI InChI=1S/C24H26Cl2FN5O2/c1-13-10-29-6-7-32(13)21-9-19(33-3)16(12-30-21)15-8-20(24(28)31-11-15)34-14(2)22-17(25)4-5-18(27)23(22)26/h4-5,8-9,11-14,29H,6-7,10H2,1-3H3,(H2,28,31)/t13-,14+/m0/s1; Key:BVGDAZBTIVRTGO-UONOGXRCSA-N;

Last updated January 12, 2026

Envonalkib is a pharmaceutical drug for cancer treatment.^[1] It belongs to the class of anaplastic lymphoma kinase inhibitors (ALK inhibitors).^[2]

In China, it is approved for the treatment of patients with ALK-positive locally advanced or metastatic non-small cell lung cancer (NSCLC) who have not received treatment with ALK inhibitors.^[3]

References

↑ Yang Y, Min J, Yang N, Yu Q, Cheng Y, Zhao Y, et al. (August 2023). "Envonalkib versus crizotinib for treatment-naive ALK-positive non-small cell lung cancer: a randomized, multicenter, open-label, phase III trial". Signal Transduction and Targeted Therapy. 8 (1) 301. doi:10.1038/s41392-023-01538-w. PMC 10423717 . PMID 37574511.
↑ Damuzzo V, Gasperoni L, Del Bono L, Ossato A, Inno A, Messori A (2025). "Treatment of metastatic ALK-positive non-small cell lung cancer: indirect comparison of different ALK inhibitors using reconstructed patient data". Frontiers in Oncology. 15 1566816. doi: 10.3389/fonc.2025.1566816 . PMC 12098575 . PMID 40416880.
↑ "Envonalkib Citrate Capsules Approved for Marketing by China NMPA". National Medical Products Administration. 2025-02-19.

This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it.

This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.

[1] Yang Y, Min J, Yang N, Yu Q, Cheng Y, Zhao Y, et al. (August 2023). "Envonalkib versus crizotinib for treatment-naive ALK-positive non-small cell lung cancer: a randomized, multicenter, open-label, phase III trial". Signal Transduction and Targeted Therapy. 8 (1) 301. doi:10.1038/s41392-023-01538-w. PMC 10423717 . PMID 37574511.

[2] Damuzzo V, Gasperoni L, Del Bono L, Ossato A, Inno A, Messori A (2025). "Treatment of metastatic ALK-positive non-small cell lung cancer: indirect comparison of different ALK inhibitors using reconstructed patient data". Frontiers in Oncology. 15 1566816. doi: 10.3389/fonc.2025.1566816 . PMC 12098575 . PMID 40416880.

[3] "Envonalkib Citrate Capsules Approved for Marketing by China NMPA". National Medical Products Administration. 2025-02-19.

[1]

[2]

[3]